(NASDAQ: EVO) Evotec Se's forecast annual revenue growth rate of 4.65% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.26%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.78%.
Evotec Se's revenue in 2025 is $903,873,255.On average, 1 Wall Street analysts forecast EVO's revenue for 2025 to be $171,690,480,629, with the lowest EVO revenue forecast at $171,690,480,629, and the highest EVO revenue forecast at $171,690,480,629. On average, 1 Wall Street analysts forecast EVO's revenue for 2026 to be $176,148,865,477, with the lowest EVO revenue forecast at $176,148,865,477, and the highest EVO revenue forecast at $176,148,865,477.
In 2027, EVO is forecast to generate $184,146,582,156 in revenue, with the lowest revenue forecast at $184,146,582,156 and the highest revenue forecast at $184,146,582,156.